Egbert F Smit (Egbert Smit)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 29

Top Topics

Cerebrospinal Fluid

Tyrosine Kinase

Metastatic Colorectal Cancer

Top Venues

NPJ precision oncology

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

David Planchard, Rachel E Sanborn, Marcelo Vailati Negrão, Aria Vaishnavi, Egbert F Smit
BRAF V600E -mutant metastatic NSCLC: disease overview and treatment landscape. NPJ precision oncology 8 (1) (2024)
David Planchard, Rachel E Sanborn, Marcelo Vailati Negrão, Aria Vaishnavi, Egbert F Smit
BRAF V600E -mutant metastatic NSCLC: disease overview and treatment landscape. NPJ precision oncology 8 (1) (2024)
J W Tijmen van der Wel, Mirjam C Boelens, Merel Jebbink, Sietske A Smulders, Klaar W Maas, Merel J A Luitse, Annette Compter, Robin P B Boltjes, Nik Sol, Kim Monkhorst, Daan van den Broek, Egbert F Smit, Adrianus Johannes de Langen, Dieta Brandsma
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of EGFR mutated NSCLC patients developing leptomeningeal metastases: ORA-LM study. Neuro-oncology (2024)
David Planchard, Rachel E Sanborn, Marcelo Vailati Negrão, Aria Vaishnavi, Egbert F Smit
BRAF V600E -mutant metastatic NSCLC: disease overview and treatment landscape. NPJ precision oncology 8 (1) (2024)
David Planchard, Rachel E Sanborn, Marcelo Vailati Negrão, Aria Vaishnavi, Egbert F Smit
BRAF V600E -mutant metastatic NSCLC: disease overview and treatment landscape. NPJ precision oncology 8 (1) (2024)
Karlijn Hummelink, Vincent van den Noort, Mirte Muller, Robert D Schouten, Michel van den Heuvel, Daniela S Thommen, Egbert F Smit, Gerrit A Meijer, Kim Monkhorst
Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer. PloS one 19 (7) (2024)
David Planchard, Rachel E Sanborn, Marcelo Vailati Negrão, Aria Vaishnavi, Egbert F Smit
Author Correction: BRAF V600E -mutant metastatic NSCLC: disease overview and treatment landscape. NPJ precision oncology 8 (1) (2024)
David Planchard, Rachel E Sanborn, Marcelo Vailati Negrão, Aria Vaishnavi, Egbert F Smit
BRAF V600E -mutant metastatic NSCLC: disease overview and treatment landscape. NPJ precision oncology 8 (1) (2024)
Joris van de Haar, Joanne M Mankor, Karlijn Hummelink, Kim Monkhorst, Egbert F Smit, Lodewyk F A Wessels, Edwin Cuppen, Joachim G J V Aerts, Emile E Voest
Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (7) (2024)
David Planchard, Rachel E Sanborn, Marcelo Vailati Negrão, Aria Vaishnavi, Egbert F Smit
BRAF V600E -mutant metastatic NSCLC: disease overview and treatment landscape. NPJ precision oncology 8 (1) (2024)
Karlijn Hummelink, Vincent van den Noort, Mirte Muller, Robert D Schouten, Michel van den Heuvel, Daniela S Thommen, Egbert F Smit, Gerrit A Meijer, Kim Monkhorst
Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer. PloS one 19 (7) (2024)
Karlijn Hummelink, Vincent van den Noort, Mirte Muller, Robert D Schouten, Michel van den Heuvel, Daniela S Thommen, Egbert F Smit, Gerrit A Meijer, Kim Monkhorst
Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer. PloS one 19 (7) (2024)
David Planchard, Rachel E Sanborn, Marcelo Vailati Negrão, Aria Vaishnavi, Egbert F Smit
BRAF V600E -mutant metastatic NSCLC: disease overview and treatment landscape. NPJ precision oncology 8 (1) (2024)
Dirk Jan A R Moes, Jeroen J M A Hendrikx, Henk-Jan Guchelaar, Ron H J Mathijssen, J L Bakker, Vincent O Dezentjé, Nikki de Rouw, Nielka P van Erp, Egbert F Smit, Michel van den Heuvel, Thijs H Oude Munnink, Maartje van Kats, Sander Croes, Judith R Kroep, Juliette Zwaveling, Rob Ter Heine
Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab Govitecan. Targeted oncology (2024)
David Planchard, Rachel E Sanborn, Marcelo Vailati Negrão, Aria Vaishnavi, Egbert F Smit
BRAF V600E -mutant metastatic NSCLC: disease overview and treatment landscape. NPJ precision oncology 8 (1) (2024)
Julianne Cynthia de Ruiter, Adrianus Johannes de Langen, Kim Monkhorst, Alexander Veenhof, Houke M Klomp, Jasper Smit, Egbert F Smit, Ronald A M Damhuis, Koen J Hartemink
Survival difference between patients with single versus multiple metastatic lymph nodes and the role of histology in pathological stage II-N1 non-small cell lung cancer. Acta chirurgica Belgica (2024)
David Planchard, Rachel E Sanborn, Marcelo Vailati Negrão, Aria Vaishnavi, Egbert F Smit
BRAF V600E -mutant metastatic NSCLC: disease overview and treatment landscape. NPJ precision oncology 8 (1) (2024)
David Planchard, Rachel E Sanborn, Marcelo Vailati Negrão, Aria Vaishnavi, Egbert F Smit
Author Correction: BRAF V600E -mutant metastatic NSCLC: disease overview and treatment landscape. NPJ precision oncology 8 (1) (2024)
Joris van de Haar, Joanne M Mankor, Karlijn Hummelink, Kim Monkhorst, Egbert F Smit, Lodewyk F A Wessels, Edwin Cuppen, Joachim G J V Aerts, Emile E Voest
Combining genomic biomarkers to guide immunotherapy in non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Karlijn Hummelink, Renaud Tissier, Linda J W Bosch, Oscar Krijgsman, Michel van den Heuvel, Willemijn S M E Theelen, Diane Damotte, Francois Goldwasser, Karen Leroy, Egbert F Smit, Gerrit A Meijer, Daniela S Thommen, Kim Monkhorst
A dysfunctional T cell gene signature for predicting non-response to PD-1 blockade in non-small cell lung cancer that is suitable for routine clinical diagnostics. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, Enriqueta Felip Font, Suresh R Ramalingam, Anne S Tsao, Melissa Lynne Johnson, Francesco Gelsomino, Raymond Esper, Ernest Nadal, Michael D Offin, Mariano Provencio Pulla, Jeffrey Clarke, Maen Hussain, Gregory A Otterson, Ibiayi Dagogo-Jack, Jonathan Wade Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul S Wissel, Keith Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E Johnson
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF V600 -Mutant Metastatic Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Helena Alexandra Yu, Yasushi Goto, Hidetoshi Hayashi, Enriqueta Felip Font, James Chih-Hsin Yang, Martin Reck, Kiyotaka Yoh, Se-Hoon Lee, Luis G Paz-Ares, Benjamin Besse, Paolo Bironzo, Dong Wan Kim, Melissa Lynne Johnson, Yi-Long Wu, Thomas John, Steven Kao, Toshiyuki Kozuki, Erminia Massarelli, Jyoti D Patel, Egbert F Smit, Karen L Reckamp, Qian Dong, Pomy Shrestha, Pang-Dian Fan, Parul Patel, Andrea Sporchia, David W Sternberg, Dalila Sellami, Pasi A Janne
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Zofia Piotrowska, Daniel Shao-Weng Tan, Egbert F Smit, Alexander I Spira, Ross Andrew Soo, Danny Nguyen, Victor Ho Fun Lee, James Chih-Hsin Yang, Vamsidhar Velcheti, John M Wrangle, Mark A Socinski, Marianna Koczywas, John E Janik, Jeffrey Jones, Helena Alexandra Yu
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Koichi Goto, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, Sang-We Kim, David Planchard, Myung-Ju Ahn, Egbert F Smit, Adrianus Johannes de Langen, Maurice Pérol, Elvire Pons-Tostivint, Silvia Novello, Hidetoshi Hayashi, Junichi Shimizu, Dong Wan Kim, Chih-Hsi Kuo, James Chih-Hsin Yang, Kaline Pereira, Fu-Chih Cheng, Ayumi Taguchi, Yingkai Cheng, Wenqin Feng, Zenta Tsuchihashi, Pasi A Janne
Trastuzumab Deruxtecan in Patients With HER2 -Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Aldo A Acosta-Medina, Paul Geraeds Kemps, Timo Ce Zondag, Jithma P Abeykoon, Jelske Forma-Borst, Eline Christine Steenwijk, Elizabeth Arnoldina Maria Feijen, Jop C Teepen, N Nora Bennani, Susan M Schram, Mithun Vinod Shah, Caroline Davidge-Pitts, Matthew J Koster, Jay H Ryu, Robert Vassallo, William Oliver Tobin, Jason R Young, Surendra Dasari, Karen L Rech, Aishwarya Ravindran, Arjen Hg Cleven, Robert M Verdijk, Carel J M van Noesel, Brian V Balgobind, Gerrit J Bouma, Peerooz Saeed, Jos A M Bramer, Ruben Al de Groen, Joost S P Vermaat, Michiel Adreanus van de Sande, Egbert F Smit, Anton W Langerak, J Tom van Wezel, Sanne H Tonino, Cor van den Bos, Jan A M van Laar, Ronald S Go, Gaurav Goyal, Astrid G S van Halteren
BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis. Blood (2023)
Rolof G P Gijtenbeek, Vincent van den Noort, Joachim G J V Aerts, Jeske A Staal-van den Brekel, Egbert F Smit, Frans H Krouwels, Frank A Wilschut, Thijo Jeroen N Hiltermann, Hidde J Haisma, Ed Schuuring, Joost D J Janssen, Martijn Goosens, Paul M van den Berg, A Joop de Langen, Jos A Stigt, Ben E E M van den Borne, Harry J M Groen, Wouter H Van Geffen, Anthonie J van der Wekken
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR -mutated nonsmall cell lung cancer. ERJ open research 8 (4) (2022)
Karlijn Hummelink, Vincent van den Noort, Mirte Muller, Robert D Schouten, Ferry Lalezari, Dennis Peters, Willemijn S M E Theelen, Viktor Hendrik Koelzer, Kirsten D Mertz, Alfred Zippelius, Michel van den Heuvel, Annegien Broeks, John B A G Haanen, Ton N M Schumacher, Gerrit A Meijer, Egbert F Smit, Kim Monkhorst, Daniela S Thommen
PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (22) (2022)
Gregory J Riely, Myung-Ju Ahn, Enriqueta Felip Font, Suresh R Ramalingam, Egbert F Smit, Anne S Tsao, Ann Alcasid, Tiziana Usari, Paul S Wissel, Keith D Wilner, Bruce E Johnson
Encorafenib plus binimetinib in patients with BRAF V600 -mutant non-small cell lung cancer: phase II PHAROS study design. Future oncology (London, England) 18 (7) (2021)
Egbert F Smit, Christophe Dooms, Jo Raskin, Ernest Nadal, Lye M Tho, Xiuning Li, Julien Mazieres, Soon Hin How, Masahiro Morise, Viola W Zhu, Daniel Shao-Weng Tan, Kristina H Holmberg, Barbara Ellers-Lenz, Svenja Adrian, Sabine Brutlach, Karl M Schumacher, Niki Karachaliou, Yi-Long Wu
INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET -amplified NSCLC and first-line osimertinib resistance. Future oncology (London, England) 18 (9) (2021)